MAGELIA
Financiado
A disruptive Magnetically Enhanced Library preparation platform for Next Generat...
A disruptive Magnetically Enhanced Library preparation platform for Next Generation Sequencing
Inorevia is a spin-off from the Institut Curie/CNRS (Paris) that leverages over ten years of research in microfluidics to tackle challenges of modern Biology and Medicine with faster, cheaper, miniaturised sample preparation. Inor...
Inorevia is a spin-off from the Institut Curie/CNRS (Paris) that leverages over ten years of research in microfluidics to tackle challenges of modern Biology and Medicine with faster, cheaper, miniaturised sample preparation. Inorevia’s ground-breaking biology platform, the MAGELIA, will provide Biologists and Clinicians with a unique tool to efficiently process raw biological samples upstream of advanced analysis methods such as Next-Generation Sequencing (NGS) in volumes 100 to 1000 times smaller, in an entirely automated platform.
After over 2 years of R&D and a first TRL6 prototype of the MAGELIA platform, Inorevia is ready to accelerate its development to reach TRL8, finish the development of the MAGELIA and initiate its commercialization by 2021. Aiming for the NGS sample preparation market, this first generation of the MAGELIA platform will meet the needs of low to medium throughput labs, sequencing platforms, biotech and pharmacy companies, who struggle with low-reproducibility manual library preparations, expensive reagents, and scarce biological samples. The MAGELIA platform will democratise NGS to ignite a revolution in genomics on a fast-growing 8 Billion € market.
To succeed, Inorevia has put together an 8 persons’ team of recognized scientists, engineers, and confirmed business talents, backed by a renowned advisory board. The company holds exclusive rights on 4 key patents and large know-how. Since its inception in 2016, Inorevia has won several renowned awards in France and Europe, secured over 1.3 M€ in grants and a seed round.
The MAGELIA SME Instrument Phase 2 project specifically aims at accelerating Inorevia’s go-to market through faster development, earlier pre-series and larger market reach in Europe. With the objective to reach over 400 customers and 15% of the European market within five years, with a turnover of 30 M€, INOREVIA will become the European leader in miniaturized samples preparation for modern biology and medicine.
ver más
Duración del proyecto: 25 meses
Fecha Inicio: 2019-08-05
Fecha Fin: 2021-09-30
Fecha Fin: 2021-09-30
Línea de financiación: concedida
El organismo H2020 notifico la concesión del proyecto el día 2021-09-30
Línea de financiación objetivo
El proyecto se financió a través de la siguiente ayuda:
EIC-SMEInst-2018-2020:
SME instrument
Cerrada
hace 6 años
Presupuesto
El presupuesto total del proyecto asciende a
3M€
Líder del proyecto
INOREVIA
No se ha especificado una descripción o un objeto social para esta compañía.
Perfil tecnológico
TRL
4-5
Perfil tecnológico
TRL
4-5
757.60K€ |
Participante